Description of the medicine: Clomiphencitrate (Clomiphen citras)
CLOMIPHENCITRATE (Clomiphen citras). 1- [4- (2-Diethylaminoethoxy) phenyl] -1, 2-diphenyl-2-chloro-ethylene citrate.
Synonyms: Klostilbegit, Ardomon, Chloramiphene, Clomid, Clomifeni citras, Clomivid, Clostilbergyt, Dyneric, Fertilin, Fertomid, Genozym, Gravosan, Nefimol, Omifin, Pergolime, Prolifen, Serofen, etc.
Crystal powder, white or white with a creamy tint, slightly soluble in water, sparingly soluble in alcohol.
The preparation is a mixture of the cis and trans forms of said compound; the cis isomer is more active, the content of which in the preparation is at least 50%.
The chemical structure is related to chlortrianisene (see) - a drug with estrogenic activity, and tamoxifen (an anti-estrogenic drug).
Clomiphencitrate belongs to a group of drugs called antiestrogens. Drugs in this group specifically bind to estrogen-dependent receptors (estrogen receptors) in the hypothalamus and ovaries. In small doses, they enhance the secretion of gonadotropins (prolactin, follicle-stimulating and luteinizing hormones) and stimulate ovulation. With a low content of endogenous estrogens in the body, these drugs have a moderate estrogenic effect, however, with a high level of estrogen, they have an antiestrogenic effect. By decreasing the level of circulating estrogens (inhibiting the secretion of gonadotropic hormones in high concentrations), they contribute to an increase in the secretion of gonadotropins. In large doses, these drugs can inhibit the secretion of gonadotropins. They do not possess gestagen and androgenic activity.
In connection with the indicated properties, clomiphencitrate in appropriate doses is used as a means of stimulating ovulation with anovulatory ovarian dysfunction and associated infertility, as well as with dysfunctional uterine bleeding, dysgonadotropic forms of amenorrhea and other types of pathology associated with endocrine ovulation disorders.
Clomiphencitrate is also used for breast cancer.
In connection with the stimulation of the secretion of gonadotropins, clomiphencitrate is also used for androgen deficiency, oligospermia in men and with delayed sexual and physical development in male adolescents.
Used to diagnose disorders of the pituitary gonadotropic function.
Clomiphencitrate can be used in combination with gonadotropin hormone preparations. It is well absorbed when taken orally and is slowly excreted from the body; the half-life of the drug in the body is 5 to 7 days.
Clomiphencitrate is taken orally (regardless of the meal time).
To stimulate ovulation, it is prescribed orally at a dose of 50 mg (0.05 g) 1 time per day (at bedtime), starting from the 5th day of the menstrual cycle, for 5 days.
Pre-determine the content of estrogen in the body. If there is no effect, the treatment is repeated, conducting 3-5 courses, increasing the daily dose to 75-100 mg or increasing the duration of the course to 10 days. The course dose of the drug should not be more than 500 mg.